Skip to Content

New Paper Published in "Stem Cells" Reporting In-Vivo Migration Ability of Brainstorm Cell Therapeutics' NTF Cells

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--Jul 22, 2008 - BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company's new therapeutic approach for treating neurodegenerative disease was highlighted in a recent scientific paper that was published in "Stem Cells" highlighting the company's patent technology for treating neurodegenerative diseases. "Stem Cells" is the most well known journal recording findings in the stem cell field. The paper was authored by Tel Aviv University scientists.

The paper, reporting the recent work of Laboratory of Neurosciences, FMRC, Department of Neurology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, headed by BrainStorm's Chief Consultants Prof. Eldad Melamed and Dr. Dani Offen, analyzes and discusses rat NTF cells' ability to migrate in the brain from the place of transplantation to damaged regions.

The NTF cells are generated from adult bone marrow derived stem cells, and intended for autologous transplantation in Parkinson's patients. The cells produce and secrete neurotrophic factors, which are essential for the survival and outgrowth of neurons. The production process of these cells, are Brainstorm's intellectual property. This study shows that in a rat model of Huntington's disease, a hereditary neurodegenerative disease, NTF cells that were transplanted at a distance site, migrated towards the lesion at 19 days post grafting. This finding indicates the survival, integration and migration abilities of NTF cells in the brain.

"The results of this study suggest that when our cells are transplanted into the human brain, they may know where they are needed, and may migrate to the damaged part of the brain, where they will hopefully demonstrate their therapeutic capacity, and provide trophic support for ill-functioning tissues. This recent study provides additional support that we are on the right track," commented Dr. Dani Offen, BrainStorm's Chief scientific advisor.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology is based on discoveries made by the scientific team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's initial focus is on Parkinson ALS and Spinal Cord Injury, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including BrainStorm's ability to complete its equity financing transactions previously disclosed. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; dependence on its license to Ramot's technology; ability, together with its licensor, to adequately protect the NurOwn(tm) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.


BrainStorm Cell Therapeutics Inc.
Chaim Levinson, +972-545-633683

Posted: July 2008